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ABSTRACT
Objective: To classify users of injectable hormonal contraceptives (AHI) in accordance with the safe use 
according to medical eligibility criteria of the World Health Organization (WHO) and assess the association 
between type of injection and use of time with safe use. Methods: Cross-sectional, descriptive and exploratory 
study. The population was composed by 52 users of AHI. Data were collected through interviews, which 
followed form developed by the authors, and identified factors that contraindicate or indicate the use of the 
method, classifying them into categories from 1 to 4. The project was approved by the Ethics Committee of the 
University Federal do Ceará, CAAE: 36668314.3.0000.5054. Results: Were identified 44 (84.7%) women in safe 
use and 8 (15.3%) in unsafe use. Users with over a year of use had a higher frequency of unsafe use (p=0.001). 
Conclusion: Following WHO recommendations should be routine in nursing consultation to the protection 
and safety of women.
Descriptors: Contraceptive agents; Evaluation; Medical eligibility criteria.
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RESUMO
Objetivo: Classificar usuárias de anticoncepcionais hormonais injetáveis 
(AHI) quanto ao uso seguro segundo critérios médicos de elegibilidade 
da Organização Mundial da Saúde (OMS) e verificar associação entre 
tipo de injetável e tempo de uso com o uso seguro. Métodos: Estudo 
transversal, descritivo e exploratório. A população foi composta pelas 
52 usuárias de AHI. Os dados foram coletados por meio de entrevista, 
que seguiu formulário elaborado pelas autoras, sendo identificado fatores 
que contraindicassem ou indicassem o uso do método, classificando-as 
em categorias de 1 a 4. O Projeto foi aprovado pelo Comitê de Ética em 
Pesquisa da Universidade Federal do Ceará, CAAE: 36668314.3.0000.5054. 
Resultados: Foram identificadas 44 (84,7%) mulheres em uso seguro e 8 
(15,3%) inseguro. Usuárias há mais de um ano tiveram uma frequência 
maior de uso inseguro (p=0,001). Conclusão: Seguir as recomendações 
da OMS deve ser rotina nas consultas de enfermagem visando à proteção 
e segurança da mulher.
Descritores: Anticoncepcionais; Avaliação; Critérios Médicos 
de Elegibilidade.
RESUMEN
Objetivo: Clasificar las usuarias de anticonceptivos hormonales inyectables 
(AHI) segundo criterio de elegibilidad médica de la Organización Mundial 
de la Salud (OMS) y evaluar la asociación entre el tipo de inyección y el 
uso del tiempo con uso seguro. Métodos: Estudio transversal, descriptivo 
y exploratorio. La población fue compuesta por 52 usuarias de AHI. Los 
datos fueron colectados a través de entrevistas desarrollada por las autoras, 
e identificó los factores que contraindican o indiquen el uso del método, 
clasificándolos en categorías 1 a 4. El proyecto fue aprobado por el Comité 
de Ética de Investigación de la Universidad Federal do Ceará, CAAE: 
36668314.3.0000.5054. Resultados: Se identificaron 44 (84,7%) mujeres en 
el uso seguro y 8 (15,3%) no seguro. Las usuarias más de un año habían 
una mayor frecuencia de uso inseguro (p=0,001). Conclusión: El uso de las 
recomendaciones de la OMS debe ser rutinario en la consulta de enfermería.
Descriptores: Anticonceptivos, Evaluación, Criterios médicos 
de elegibilidad.
INTRODUCTION 
Injectable Hormonal Contraceptives (AHI) are the most 
effective methods among reversible contraceptives, with a 
high number of users in Brazil and in other countries of 
the world. 
A study carried out in Brazil, with 343 women, found 
that the participants used a variety of contraceptive methods, 
with hormonal prevalence (105 - 30.6%), with AHI being 
used by 8.2% of women.1
AHI are the most used methods in regions such as 
Ethiopia, where their use rose from 3.0% in 2000 to 21.0% 
in 2011, being used by 14.0% of women of childbearing age 
residing in that country; And Sub-Saharan Africa, with 9 
million users, making up 43.0% of total contraceptive use.2
In Brazil, AHI offered by the Unified Health System 
(SUS) is found in two presentations, being the monthly 
(combined) and the quarterly (exclusive of progestogen). 
The monthly HIAs contain an ester of a natural estrogen, 
estradiol, and a synthetic progestogen. The trimesters have 
150 mg Medroxyprogesterone Acetate Deposit (AMP-D).3 
The use of AMP-D is highlighted in situations where there 
is contraindication of the estrogen hormone, such as in the 
presence of cardiovascular diseases, smoking associated with 
age above 35 years, exclusive breastfeeding and obesity.4 
Despite the benefits offered by AHI to their users, these 
methods can cause some side effects and complications such 
as menstrual changes (irregular menstrual cycle, increased or 
decreased flow, and even amenorrhea), mastalgia, headache, 
dizziness, nausea, increase Weight loss, fluid retention, acne, 
thromboembolic complications, myocardial infarction, 
arterial hypertension, and stroke. The development of these 
events depends mainly on the type of hormone used, its 
dosage and the presence of associated diseases.5 
It is essential that the health professional is able to perform 
the clinical follow-up of the user, guiding the selection and 
correct use of AHI, its side effects and complications.
In order to assist the health professional in the 
management of contraceptive methods (indication of the 
method or not), the World Health Organization (WHO) 
Eligibility Criteria for Use of Contraceptive Methods (CME) 
is available.6 
The CMEs endorsed by WHO are defined as the set of 
characteristics presented by the candidate to use a particular 
method, which indicates whether or not it can use it. They 
are arranged in four categories: Category 1 - the method 
can be used without restrictions; Category 2 - the method 
can be used with restrictions, which are situations in which 
the advantages of using it usually outweigh the proven or 
theoretical risks that its use could entail, that is, the method 
is not the first choice and, if used, More careful monitoring 
is necessary; Category 3 - the proven and theoretical risks 
arising from the use of the method generally outweigh the 
benefits - when there is Category 3 condition for a method, 
it should be the last choice and, if chosen, it is necessary to 
follow the user strictly ; Category 4 - the method should not 
be used as it poses an unacceptable risk.6
The correct and consistent use of AHI depends on 
factors related to the woman, the method and the health 
professional. The application of CMEs will favor an adequate 
clinical practice by the health professional, which will 
consequently result in greater safety for the user. The safe use 
of a contraceptive method implies a lesser exposure of the 
user to the risks of complications.6
Considering the importance of the CMEs as a support 
for the health professional to carry out the evaluation of 
the candidate for the use of AHI, the following research 
questions were elaborated: In which WHO category, AHI 
users accompanied in a family planning service would 
be classified? Is there an association between type of AHI 
and time of use with WHO categories attributed to users, 
according to the CME? 
The objective of the study was to classify AHI users 
for WHO categories and to verify the association between 
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the type of injectable and the time of use with the WHO 
categories attributed to the users.
METHOD
This is a cross-sectional, descriptive and exploratory 
research, carried out in a unit belonging to the Hospital 
Complex of the Federal University of Ceará (UFC), 
located in the outskirts of the Municipality of Fortaleza, 
Ceará. The unit is used as a field of practice for students of 
several courses in the health area, to highlight the Nursing 
Undergraduate Course.
At the site, Nursing students offer family planning 
services, with Nursing consultations and health education 
activities. These activities are carried out under the 
supervision of professors and students of the postgraduate 
course in Nursing of the UFC (Masters and Doctorate). 
The research population consisted of 52 AHI users 
followed in the referred service, constituting the sample of 
the research where all participated. The data were collected 
through an interview, following a structured form, which 
was elaborated by the authors. The form was composed of 
open and closed questions, addressing the socioeconomic 
data, type of AHI in use and time of use; and a screening 
system developed on the basis of the WHO CME, allowing 
to register the clinical conditions of the participants. After 
the clinical analysis of AHI users, women were classified 
in the categories proposed by the WHO: category 1, the 
method is indicated in any circumstances; Category 2, the 
method can generally be used; Category 3, the method is 
generally not recommended unless other more appropriate 
methods are not available or are not acceptable; Category 
4, the method should not be used. The WHO also proposes 
for the circumstances in which there are limited resources 
for clinical judgment to join categories 1 and 2, using 
the indicated method, and junctions of categories 3 and 4 
being the use of contraindicated method. In these terms, 
the results related to this theme were discussed according 
to this parameter of joining the categories, considering the 
characteristics of the service searched.
The interviews were conducted in a private setting, 
previously selected for this purpose. They had an average 
duration of 20 minutes and occurred between the months of 
November/2014 and April/2015.
The data were organized in Excel for Windows and 
analyzed in the Statistical Package for Social Science (SPSS), 
version 20.0, license number: 10101131007. A descriptive 
statistical analysis of the results was carried out and Fisher’s 
Exact Test was applied to verify the associations between 
type of AHI and time of use with WHO categories attributed 
to AHI users, where significance was set at a value of p <0.05. 
The Research Project was approved by the Research Ethics 
Committee of the Federal University of Ceará, according to 
CAAE protocol: 36668314.3.0000.5054, opinion no. 851,453.
RESULTS 
Participants ranged in age from 16 to 41 years, with 
a predominance of 20 to 34 years old, corresponding to 
32 (61.5%) of the total interviewees. The other 20 (38.4%) 
women were at the reproductive ends.
In relation to schooling, 34 (65.3%) had 10 to 12 years of 
schooling, demonstrating that these women had at least high 
school education. Just over half of the women had a fixed 
partner, corresponding to 27 (52%). 
There was a predominance of participants who declared 
themselves to be at home, that is, 36 (69.3%), followed by 
16 (30.7%) who stated that they had paid work and/or 
were studying. 
Of the 52 participants, 35 (67.3%) were users of 
Combined Injectable Contraceptive (ICA) and 17 (32.7%) 
of Exclusive Progestogen Injectable Contraceptive (AIEP). 
In Table 1, AHI were presented by type and according to the 
time of use.
Table 1 - Distribution of the number of users of injectable 
hormonal contraceptives according to time of use. Fortaleza/
CE, November 2014 - April 2015
Type of 
hormonal
Usage time (month)
1-12 13-24 25-36 37-48 120 -156
n % N % n % n % n %
*AIC 
(n=35)
19 54.2 9 25.7 2 5.8 3 8.5 2 5.8
**AIEP 
(n=17)
13 76.4 3 17.7 --- --- --- --- 1 5.9
Subtitle: *AIC - Combined injectable contraceptive; **AIEP - Progestin-
only injectable contraceptive
A total of 33 (63.4%) AHI users were identified, 
accompanied by the family planning service, in Category 
1, that is, the method can be used without restrictions; 
11 (21.1%) women were evaluated in Category 2, which 
indicates, in general, the use of the method; 3 (5.8%) 
women were classified in Category 3, ie the method is not 
recommended, unless other more appropriate methods are 
not available or are not acceptable; and 5 (9.7%) users were 
classified in Category 4, that is, the method should not be 
used because it presents an unacceptable risk. 
Among the three AHI users classified as Category 3, 1 
(1.9%) users of AIC were classified as reporting migraine 
without aura and being younger than 35 years as CME. The 2 
(3.8%) AIEP users who were also in Category 3, one was due 
to migraine with aura and the other due to having diastolic 
blood pressure equal to 100 mmHg.
The five AHI users classified in Category 4 reported with 
migraine CME with focal neurological signs and aura, which 
contraindicates the use of the method at any age.
The association between the AHI and the time of use 
with the categories of the CME attributed to the users is 
found in Table 2.
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Table 2 - Association between type of AHI and time of 
use with categories of CME/WHO attributed to the users. 
Fortaleza, CE, Brazil, November 2014 – abril 2015
Variables (n=52)
Categories 
1 e 2
Categories 
3 e 4
Valor 
de p
N % n %
**Type of AHI *1.000
***AIC 29 82.9 6 17.1
****AIEP 15 88.2 2 11.8
Time of use *0.011
Up to 1 year 37 92.5 3 7.5
More than 1 year 7 58.3 5 41.7
Legend: * Fisher’s Exact Test; ** Injectable hormonal contraceptive 
(HIA); *** Combined injectable contraceptive (AIC); **** Progestin-only 
injectable contraceptive (AIEP).
DISCUSSION
The AHI use time ranged from 1 to 156 months. The 
majority of users focused on the use time of up to 24 months, 
corresponding to 28 (79.9%) of ICA users and 16 (94.1%) of 
ICU users, that is, the majority of users Of AHI continued 
the use of the method until that period, when, from then 
on, the percentage of users reduced sharply, with 8 (18.6%) 
using the method a considerable length of time (more than 
24 months). Therefore, it can be observed that with the 
increase of the time of AHI use, the percentage of users tends 
to decrease.
The aforementioned finding is corroborated in the 
analysis of 60 Demographic and Health Surveys (DHS) that 
occurred in the years 1990 to 2009. This review concluded 
that the probability of interrupting the use of AHI at 12 
months was 41.0 %. In 24 months it was 65%; and in 36 
months it was 74%. The reasons for discontinuation were 
related to the type of AHI, side effects and health problems.7 
Thus, the increase in AHI use time seems to influence the 
interruption of the method.
Another aspect observed is that the percentage of AIEP 
users was higher than the percentage of AIC users in the 
first year, a relation that is reversed in the second year, when 
the percentage of AIC users is higher than the AIEP users. 
Research conducted in Nigeria found that there is a high rate 
of continuation of AIEP and that many users were using the 
method for 12 months.8
In Honduras, authors found that women who had 
used a MAC for less than 12 months or discontinued use 
compared to women who had used a method for more than 
one year were significantly more likely to change and stop 
the method used.9 
The emergence of side effects, especially those related 
to changes in the menstrual flow, is the main reason for the 
discontinuation of the use of AHI, of the type Acetate of 
medroxyprogesterone deposition (AMP-D) and Cyclofem®.10 
Therefore, adequate guidance to the HIA user about side 
effects and their management is essential in order to avoid 
discontinuation of the method. 
Several factors interfere in the continuation and, 
consequently, in the time of contraceptive use, such as side 
effects, difficulty of access, lack of knowledge on how to deal 
with the method, among others. In the service researched, 
access to the method is facilitated by the application of the 
injection in the Nursing consultation itself, where also the 
ample information is valued to the client, both in the sense of 
understanding the use and operation of the injectable and in 
the sense of dealing with the side effects. Thus, it is important 
to investigate the reasons that are leading the group to 
discontinue the use of AIEP in the second year.
Despite the presentation of the four categories of WHO, 
with their respective indications for contraceptive use, 
including AHI, the WHO itself recommends for the regions 
and/or services with limited clinical follow-up, the junction 
of category 1 and 2, defining Such as “Yes, use method”; and 
category 3 to 4, setting it to “No, do not use method”.6 
Therefore, among the AHI users surveyed, 44 (84.7%) 
were classified in categories 1 or 2, in which AHI can be 
used. This reflects the adequate Nursing follow-up offered in 
the family planning service of the service researched, where 
the Nursing consultation covers the physical examination 
of the users, the interview based on the CME, listening for 
the most common complaints and guidelines for users to 
exercise co-responsibility By the safe use of the AHI.
On the other hand, 8 (15.3%) users were classified in 
categories 3 or 4, which contraindicated the use of AHI.
Observing the CMEs identified in those users (a case 
of migraine without aura with age less than 35 years, one 
case of diastolic blood pressure equal to 100 mmHg and six 
cases of migraine with focal neurological signs with aura), 
it was verified that they could preexisting to the use of AHI, 
but could also have been developed in the course of its use, 
an aspect that does not legitimize the finding of the poor 
quality of the service. However, these results reinforce the 
importance of careful assessment of these users in the first 
time (to start the method) and in the return visits, always 
based on CME.
A study conducted in Fortaleza-CE with women with 
diabetes mellitus found very similar results, when 92 (88.4%) 
participants used MAC in WHO Category 1 or 2 and 12 
(11.6%) used MAC in Categories 3 or 4.11 
In a study conducted with 264 women, also in 
Fortaleza-CE, addressing the safe use of combined low-dose 
oral contraceptives based on CME, 91 (35.0%) users were 
identified in Categories 3 or 4, a much higher percentage of 
than the one found in the present research and research cited 
above. The CMEs responsible for these results were: smoking 
(less than 15 cigarettes per day) associated with age> 35 years 
(4), blood pressure (systolic 140-159, diastolic 90-99 mmHg), 
cardiovascular disease, personal history of thrombosis Deep 
vein thrombosis (DVT) and complicated valvular heart 
disease (11), headache with migraine and age <35 years (47), 
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liver disease (2), migraine headache and age> 35 years (14), 
headache with aura 12) and past breast cancer (1) woman.12
A study conducted in the United Kingdom found 
that with the use of WHO-endorsed WHO, there was a 
decrease in combined hormonal contraceptive prescriptions 
for women who were in Categories 3 and 4 for MAC use, 
however, the method was still prescribed for women who 
possessed Risk of developing cardiovascular disease.13 
Often, the small range of contraceptive methods in health 
services justifies this reality, as well as the client’s resistance 
to changing methods.
Nurses and/or nursing students under supervision 
should remain vigilant during Family Planning Nursing 
consultations, as a clinical reevaluation of the IHI user is 
required, as well as the guidelines that should be sought with 
the users to encourage safe use Of the AHI. 
Being in Categories 1 and 2 or WHO Categories 3 and 
4 as an AHI user had no association with type of AHI and 
duration of use of the injectable (values of p = 1,000 and 
0.011, respectively). However, the percentage of AHI users 
in Categories 1 and 2 was predominant in the first year of 
use, while the percentage of users in Categories 3 and 4 was 
predominantly pronounced in the second year of use.
The main contribution of this study is the demonstration 
of the relevance of the use of CME in Nursing consultations 
in family planning.
It is important to emphasize, as a limitation of the study, 
the reduced size of the sample, which was due to the fact that 
it represents the group served in a service only. 
CONCLUSION
Among the AHI users surveyed, 44 (84.7%) were 
classified in categories 1 or 2, from WHO; And 8 (15.3%) 
users were classified in categories 3 or 4. Being in Categories 
1 and 2 or WHO Categories 3 and 4 as an AHI user had 
no association with type of AHI and duration of use of the 
injectable ( Values of p> 0.05). However, as the percentage of 
AHI users in Categories 1 and 2 was predominant in the first 
year of use, while the percentage of users in Categories 3 and 
4 was predominantly accentuated in the second year of use, 
it is important to maintain vigilance to the health of the user 
as the time of use of the AHI increases. 
Thus, nurses and Nursing students under supervision, 
who carry out family planning Nursing consultations, should 
maintain the use of CME in the approach of AHI users, in 
order to promote the safe use of the method. 
It is suggested to carry out new researches that 
contemplate the evaluation of users of other hormonal 
methods and the classification according to the CME.
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